Mylan Settles Patent Dispute - Analyst Blog
14 Março 2013 - 10:40AM
Zacks
Mylan Inc. (MYL)
recently announced that it has inked a deal with Shionogi Inc. and
Andrx to settle a patent-related dispute pertaining to the generic
version of Shionogi's Fortamet. The drug is marketed as an
adjunct to diet and exercise to bring down the level of glucose in
the blood.
Following the agreement, Mylan can start selling its generic
version of Fortamet from Aug 1, 2013, or earlier under certain
circumstances. Mylan did not disclose the other terms of the deal.
The transaction will be reviewed by the US Department of Justice
and the Federal Trade Commission.
The resolution of the patent-related dispute regarding Fortamet has
removed a significant overhang for Mylan and represents further
good news for the generic unit of the company. We note that the
company has received quite a few approvals on the generic front
over the past few months.
Our Take
Mylan’s geographic reach and product depth, along with a robust
generic pipeline, are contributing to its overall growth. We are
also pleased with Mylan’s focus on emerging markets. Over the long
term, the biggest opportunities for growth in the generics industry
would be expansion in emerging markets.
However, we remain cautious of the company’s performance in Europe,
Middle East and Africa. Additionally, as most of the large branded
drugs are due to lose patent exclusivity within the 2017–2018
period, we have little visibility on the growth prospects of
generic companies like Mylan beyond that timeframe.
Mylan carries a Zacks Rank #2 (Buy). Companies like Lannett
Company, Inc. (LCI), WuXi
PharmaTech (Cayman) Inc. (WX) and QLT
Inc. (QLT) look more attractive in the pharma space with a
Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
(QLT): Get Free Report
WUXI PHARMATECH (WX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Quantshares U.S. Market Neutral Quality Fund Etf (AMEX:QLT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Quantshares U.S. Market Neutral Quality Fund Etf (AMEX:QLT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Quantshares U.S. Market Neutral Quality Fund Etf da American Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Quantshares U.S. Market Neutral Quality Fund Etf